WithdrawnPhase 4

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Stopped: Sponsor strategic decision

0Started 2022-08-29

Plain-language summary

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 to 65 year of age * Major Depressive Disorder (MDD) with symptoms of anxiety * Stable treatment with less than 50% improvement Exclusion Criteria: * Contraindicated to perform fMRI scan * Previous exposure to brexpiprazole

What they're measuring

Change in fMRI resting-state salience network community structure from baseline to post-treatment

Timeframe: Week 6

Trial details

NCT IDNCT05504486

SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-03-22

View on ClinicalTrials.gov More Major Depressive Disorder (MDD) trials